Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine.
- 1 January 1997
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 14 (8), 1019-1025
- https://doi.org/10.1023/a:1012197110917
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell linesEnvironmental Toxicology and Pharmacology, 1996
- In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.1995
- Expression of cytochrome P‐450 3A in HT29‐MTX cells and Caco‐2 clone TC7FEBS Letters, 1994
- Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.1994
- Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamilyBiochemical Pharmacology, 1994
- Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation.1993
- Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.JCI Insight, 1992
- Biochemical characterization of resistance to mitoxantrone and adriamycin in Caco-2 human colon adenocarcinoma cells: a possible role for glutathione S-transferases.1992
- Cell cultures as models for drug absorption across the intestinal mucosa.1991
- The Use of Cultured Epithelial and Endothelial Cells for Drug Transport and Metabolism StudiesPharmaceutical Research, 1990